MX2020007098A - Inhibicion por pic1 de la actividad oxidativa de la mieloperoxidasa en un modelo animal. - Google Patents
Inhibicion por pic1 de la actividad oxidativa de la mieloperoxidasa en un modelo animal.Info
- Publication number
- MX2020007098A MX2020007098A MX2020007098A MX2020007098A MX2020007098A MX 2020007098 A MX2020007098 A MX 2020007098A MX 2020007098 A MX2020007098 A MX 2020007098A MX 2020007098 A MX2020007098 A MX 2020007098A MX 2020007098 A MX2020007098 A MX 2020007098A
- Authority
- MX
- Mexico
- Prior art keywords
- pic1
- subject
- myeloperoxidase
- inhibition
- animal model
- Prior art date
Links
- 102000003896 Myeloperoxidases Human genes 0.000 title abstract 3
- 108090000235 Myeloperoxidases Proteins 0.000 title abstract 3
- 101100243951 Caenorhabditis elegans pie-1 gene Proteins 0.000 title 1
- 238000010171 animal model Methods 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000001590 oxidative effect Effects 0.000 title 1
- 101100153168 Arabidopsis thaliana TIC21 gene Proteins 0.000 abstract 4
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 abstract 4
- 101100273813 Homo sapiens CDKN1A gene Proteins 0.000 abstract 4
- 108700038981 SUMO-1 Proteins 0.000 abstract 4
- 101100083337 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pic1 gene Proteins 0.000 abstract 4
- 208000007587 Transfusion-Related Acute Lung Injury Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000004154 complement system Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/00033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Wood Science & Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862615183P | 2018-01-09 | 2018-01-09 | |
| US201862681458P | 2018-06-06 | 2018-06-06 | |
| US201862746649P | 2018-10-17 | 2018-10-17 | |
| PCT/US2019/012659 WO2019139886A1 (en) | 2018-01-09 | 2019-01-08 | Pic1 inhibition of myeloperoxidase oxidative activity in an animal model |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007098A true MX2020007098A (es) | 2020-11-11 |
Family
ID=67140101
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007098A MX2020007098A (es) | 2018-01-09 | 2019-01-08 | Inhibicion por pic1 de la actividad oxidativa de la mieloperoxidasa en un modelo animal. |
| MX2025009081A MX2025009081A (es) | 2018-01-09 | 2020-07-13 | Inhibicion por pic1 de la actividad oxidativa de la mieloperoxidasa en un modelo animal |
| MX2025009095A MX2025009095A (es) | 2018-01-09 | 2020-07-13 | Inhibicion por pic1 de la actividad oxidativa de la mieloperoxidasa en un modelo animal |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025009081A MX2025009081A (es) | 2018-01-09 | 2020-07-13 | Inhibicion por pic1 de la actividad oxidativa de la mieloperoxidasa en un modelo animal |
| MX2025009095A MX2025009095A (es) | 2018-01-09 | 2020-07-13 | Inhibicion por pic1 de la actividad oxidativa de la mieloperoxidasa en un modelo animal |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US11135272B2 (https=) |
| EP (2) | EP3740074B1 (https=) |
| JP (2) | JP7031011B2 (https=) |
| KR (2) | KR20220104268A (https=) |
| CN (1) | CN112512548A (https=) |
| AU (2) | AU2019207508B2 (https=) |
| CA (1) | CA3086407A1 (https=) |
| ES (1) | ES2996888T3 (https=) |
| IL (2) | IL287308B2 (https=) |
| MX (3) | MX2020007098A (https=) |
| SG (1) | SG11202006063RA (https=) |
| WO (1) | WO2019139886A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10947279B2 (en) | 2015-06-26 | 2021-03-16 | Realta Holdings, Llc | Synthetic peptide compounds and methods of use |
| EP3740074B1 (en) | 2018-01-09 | 2024-11-06 | ReAlta Holdings, LLC | Pic1 inhibition of myeloperoxidase oxidative activity in an animal model |
| IL301441A (en) * | 2020-09-30 | 2023-05-01 | Realta Life Sciences Inc | Peptides and methods of use |
| WO2022094367A1 (en) * | 2020-11-02 | 2022-05-05 | Realta Life Sciences, Inc. | Peptides and methods of use |
| WO2022094372A1 (en) * | 2020-11-02 | 2022-05-05 | Realta Life Sciences, Inc. | Peptides and methods of use |
| CA3194447A1 (en) * | 2020-11-09 | 2022-05-12 | Neel K. Krishna | Peptide formulations and methods of use |
| WO2022179937A1 (en) * | 2021-02-26 | 2022-09-01 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Anti-cleaved histone h3 monoclonal antibody that specifically recognizes neutrophil extracellular traps |
| JP2024522988A (ja) * | 2021-06-01 | 2024-06-25 | レアルタ ライフ サイエンシズ インコーポレイテッド | ペプチドおよび使用方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5625049A (en) | 1993-05-12 | 1997-04-29 | Us Health | Nucleic acids encoding human astrovirus serotype 2 |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| AU3066699A (en) | 1998-03-03 | 1999-09-20 | Johns Hopkins University, The | Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation |
| AU2729400A (en) | 1999-01-19 | 2000-08-07 | James Daly | Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease |
| US6696562B1 (en) | 2000-07-10 | 2004-02-24 | The United States Of America As Represented By The Secretary Of Agriculture | Avian astrovirus |
| US20070012617A1 (en) | 2003-09-05 | 2007-01-18 | Sadakatsu Suzuki | Method for producing micro-porous film of thermoplastic resin |
| WO2005023296A1 (en) | 2003-09-05 | 2005-03-17 | University Of Louisville Research Foundation, Inc. | Treatment of rheumatic diseases |
| WO2005023195A2 (en) | 2003-09-05 | 2005-03-17 | University Of Louisville Research Foundation, Inc. | Treatment of spinal cord injury |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| US7381524B2 (en) | 2003-10-10 | 2008-06-03 | Wisconsin Alumni Research Foundation | Method to detect antibodies specific for type-2 turkey astrovirus |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| WO2007145806A2 (en) | 2006-06-15 | 2007-12-21 | Eastern Virginia Medical School | Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof |
| US7956161B2 (en) | 2007-04-11 | 2011-06-07 | Pestka Biomedical Laboratories, Inc. | Interferons of rhesus and cynomolgus origin and uses thereof |
| US10172950B2 (en) | 2009-06-09 | 2019-01-08 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
| EP2561367A1 (en) | 2010-04-22 | 2013-02-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations |
| US10005818B2 (en) | 2010-07-21 | 2018-06-26 | Realta Holdings, Llc | Derivative peptide compounds and methods of use |
| ES2688589T3 (es) | 2010-07-21 | 2018-11-05 | Eastern Virginia Medical School | Compuestos peptídicos para regular el sistema del complemento |
| CA2867593A1 (en) | 2012-03-16 | 2013-09-19 | Belrose Pharma, Inc. | Polymeric conjugates of c-1 inhibitors |
| ES2875498T3 (es) * | 2015-06-26 | 2021-11-10 | Realta Holdings Llc | Compuestos de péptidos sintéticos y procedimientos de uso |
| EP3740074B1 (en) | 2018-01-09 | 2024-11-06 | ReAlta Holdings, LLC | Pic1 inhibition of myeloperoxidase oxidative activity in an animal model |
-
2019
- 2019-01-08 EP EP19738307.8A patent/EP3740074B1/en active Active
- 2019-01-08 CN CN201980007577.6A patent/CN112512548A/zh active Pending
- 2019-01-08 ES ES19738307T patent/ES2996888T3/es active Active
- 2019-01-08 EP EP24203120.1A patent/EP4464716A3/en active Pending
- 2019-01-08 SG SG11202006063RA patent/SG11202006063RA/en unknown
- 2019-01-08 IL IL287308A patent/IL287308B2/en unknown
- 2019-01-08 KR KR1020227023661A patent/KR20220104268A/ko not_active Ceased
- 2019-01-08 KR KR1020207022678A patent/KR102420552B1/ko active Active
- 2019-01-08 WO PCT/US2019/012659 patent/WO2019139886A1/en not_active Ceased
- 2019-01-08 MX MX2020007098A patent/MX2020007098A/es unknown
- 2019-01-08 US US16/242,550 patent/US11135272B2/en active Active
- 2019-01-08 CA CA3086407A patent/CA3086407A1/en active Pending
- 2019-01-08 JP JP2020557135A patent/JP7031011B2/ja active Active
- 2019-01-08 AU AU2019207508A patent/AU2019207508B2/en active Active
-
2020
- 2020-04-03 US US16/839,464 patent/US11020460B2/en active Active
- 2020-07-06 IL IL275867A patent/IL275867B/en unknown
- 2020-07-13 MX MX2025009081A patent/MX2025009081A/es unknown
- 2020-07-13 MX MX2025009095A patent/MX2025009095A/es unknown
-
2021
- 2021-04-30 US US17/245,213 patent/US11712462B2/en active Active
-
2022
- 2022-02-22 JP JP2022025426A patent/JP7341268B2/ja active Active
-
2023
- 2023-06-09 US US18/332,026 patent/US12257290B2/en active Active
-
2024
- 2024-07-31 AU AU2024205230A patent/AU2024205230A1/en active Pending
-
2025
- 2025-02-19 US US19/057,376 patent/US20250177492A1/en not_active Abandoned
- 2025-09-25 US US19/339,595 patent/US20260021164A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025009081A (es) | Inhibicion por pic1 de la actividad oxidativa de la mieloperoxidasa en un modelo animal | |
| Diamond et al. | Tumor promoters and the mechanism of tumor promotion | |
| PH12020551976A1 (en) | SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS | |
| SG10201900072VA (en) | A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy | |
| CR20220545A (es) | ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2) | |
| SG10201900886RA (en) | Methods and therapeutic combinations for treating tumors | |
| PH12019502076A1 (en) | Methods for modulating an immune response | |
| MX2019012032A (es) | Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3). | |
| MX372883B (es) | Uso de anticuerpos contra claudina 18.2 para el tratamiento de cáncer. | |
| PH12017500843A1 (en) | Methods for treating ocular diseases | |
| WO2019246262A3 (en) | Methods of treating or inhibiting onset of huntington's disease | |
| MX2025010483A (es) | Uso de anticuerpos y composiciones que los comprenden para tratar enfermedades y trastornos mediados por complemento | |
| NZ757105A (en) | Methods of treating and/or preventing actinic keratosis | |
| EA201790352A1 (ru) | Терапевтическое лечение на основе анаморелина | |
| MX2021004291A (es) | Tratamiento del adenocarcinoma pancreatico metastasico. | |
| WO2020005869A3 (en) | Compositions and methods for the treatment of cancer characterized with pcsk9 expression | |
| NO984160D0 (no) | Fremgangsmåte for behandling eller forebyggelse av interstitiell cystitt | |
| NL283079A (nl) | Werkwijze voor het behandelen van een monofilamentgaren | |
| WO2020021332A3 (en) | Injection techniques for the treatment of cellulite | |
| BR112022009259A2 (pt) | Métodos para tratar, inibir ou eliminar um câncer em um indivíduo | |
| ATE8322T1 (de) | Verfahren zum bekaempfen und/oder vorbeugen von allergischen krankheiten. | |
| EP3849305A4 (en) | GENETIC MOUSE MODEL FOR AUTOIMMUNE SIDE EFFECTS AND IMMUNE CHECKPOINT BLOCKADE THERAPY | |
| Landerson | Discussion of" Behavioral therapy--Bag of tricks or point of view? Treatment for homosexuality". | |
| Umansky | MDSC as a new target for cancer immunotherapy | |
| EP3976036A4 (en) | METHODS AND USES FOR THE TREATMENT OF CANCER |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: REALTA HOLDINGS, LLC |